The National Institute on Aging (NIA) has awarded a five-year grant worth up to $5 million to support a clinical…
Articles by Marisa Horak, MS
For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment…
In a few days, the U.S. Food and Drug Administration (FDA) is expected to announce whether or not…
A draft report from the Institute for Clinical and Economic Review, known as ICER, found that there is insufficient evidence…
LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation…
A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational…
Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according…
People with mild-to-moderate Alzheimer’s disease treated for three weeks with sargramostim, a medication that activates the immune system,…
Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational…
Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s…